Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted Therapy for Persisting Symptoms After Concussion
NCT06615908Phase 1Recruiting
- Sponsor
- University of Calgary
- Start
- May 2025
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of psilocybin in Post-concussion syndrome (PCS) (2 arms), sponsored by University of Calgary. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 6 months, Rivermead Post-Concussion Symptoms Questionnaire at 6 months and 1 more. Started May 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
Post-concussion syndrome (PCS)
Beyond the preview
Go deeper on NCT06615908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06615908.